Huijun Han1, Philip H Kass, Barth L Wilsey, Chin-Shang Li. 1. University of California, Davis, CA, USA; Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
Abstract
PURPOSE: To examine the age and gender-specific trends of Schedule II opioid use among California residents, with special reference to multiple provider users (doctor shoppers). METHODS: Utilizing data from the California Prescription Drug Monitoring Program, we examined age and gender-specific trends of Schedule II opioid use during calendar years 1999-2007. Specifically, we analyzed the following: (1) the prevalence of Schedule II opioid users among California's population and (2) the proportion of these opioid users who were doctor shoppers (defined as an individual who used more than five different prescribers for all Schedule II opioids he or she obtained in a calendar year). RESULTS: Among all age and gender groups, the prevalence of Schedule II opioid users in California increased by 150%-280% and the prevalence of doctor shoppers among users increased by 111%-213% over 9 years. The prevalence of opioid users was lowest among 18-44 year old men (1.25%) and highest among 65-year and older women (5.31%) by 2007. The prevalence of doctor shoppers was approximately 1.4% among those up to age 64 years and 0.5% among those 65 years and older. The gender difference in doctor shoppers among all age groups was negligible. On average, the cumulative morphine-equivalent amount of Schedule II opioid per individual obtained per year was threefold to sixfold higher for doctor shoppers than for the general population across different age and gender groups. CONCLUSIONS: Age and gender differences in opioid use were relatively small, whereas the trends for use of opioids and multiple providers grew at a disquieting rate.
PURPOSE: To examine the age and gender-specific trends of Schedule II opioid use among California residents, with special reference to multiple provider users (doctor shoppers). METHODS: Utilizing data from the California Prescription Drug Monitoring Program, we examined age and gender-specific trends of Schedule II opioid use during calendar years 1999-2007. Specifically, we analyzed the following: (1) the prevalence of Schedule II opioid users among California's population and (2) the proportion of these opioid users who were doctor shoppers (defined as an individual who used more than five different prescribers for all Schedule II opioids he or she obtained in a calendar year). RESULTS: Among all age and gender groups, the prevalence of Schedule II opioid users in California increased by 150%-280% and the prevalence of doctor shoppers among users increased by 111%-213% over 9 years. The prevalence of opioid users was lowest among 18-44 year old men (1.25%) and highest among 65-year and older women (5.31%) by 2007. The prevalence of doctor shoppers was approximately 1.4% among those up to age 64 years and 0.5% among those 65 years and older. The gender difference in doctor shoppers among all age groups was negligible. On average, the cumulative morphine-equivalent amount of Schedule II opioid per individual obtained per year was threefold to sixfold higher for doctor shoppers than for the general population across different age and gender groups. CONCLUSIONS: Age and gender differences in opioid use were relatively small, whereas the trends for use of opioids and multiple providers grew at a disquieting rate.
Authors: Stephen T Parente; Susan S Kim; Michael D Finch; Lisa A Schloff; Thomas S Rector; Raafat Seifeldin; J David Haddox Journal: Am J Manag Care Date: 2004-11 Impact factor: 2.229
Authors: Gary M Franklin; Jaymie Mai; Thomas Wickizer; Judith A Turner; Deborah Fulton-Kehoe; Linda Grant Journal: Am J Ind Med Date: 2005-08 Impact factor: 2.214
Authors: Jennifer Brennan Braden; Ming-Yu Fan; Mark J Edlund; Bradley C Martin; Andrea DeVries; Mark D Sullivan Journal: J Pain Date: 2008-07-26 Impact factor: 5.820
Authors: Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner Journal: Clin J Pain Date: 2008 Jul-Aug Impact factor: 3.442
Authors: Mark D Sullivan; Mark J Edlund; Ming-Yu Fan; Andrea DeVries; Jennifer Brennan Braden; Bradley C Martin Journal: Pain Date: 2008-06-10 Impact factor: 6.961
Authors: Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi Journal: JAMA Date: 2008-12-10 Impact factor: 56.272
Authors: Joseph Friedman; David Kim; Todd Schneberk; Philippe Bourgois; Michael Shin; Aaron Celious; David L Schriger Journal: JAMA Intern Med Date: 2019-04-01 Impact factor: 21.873
Authors: Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte Journal: J Occup Environ Med Date: 2017-11 Impact factor: 2.162
Authors: Tessa Cheng; Will Small; Ekaterina Nosova; Robert Hogg; Kanna Hayashi; Thomas Kerr; Kora DeBeck Journal: Subst Use Misuse Date: 2020-06-26 Impact factor: 2.164
Authors: Bradley D Stein; Joshua Mendelsohn; Adam J Gordon; Andrew W Dick; Rachel M Burns; Mark Sorbero; Regina A Shih; Rosalie Liccardo Pacula Journal: J Addict Dis Date: 2016-07-22
Authors: Beatrice Setnik; Carl L Roland; Kenneth W Sommerville; Glenn C Pixton; Robert Berke; Anne Calkins; Veeraindar Goli Journal: J Pain Res Date: 2015-07-09 Impact factor: 3.133
Authors: Carla A Green; Nancy A Perrin; Brian Hazlehurst; Shannon L Janoff; Angela DeVeaugh-Geiss; David S Carrell; Carlos G Grijalva; Caihua Liang; Cheryl L Enger; Paul M Coplan Journal: Pharmacoepidemiol Drug Saf Date: 2019-04-24 Impact factor: 2.890
Authors: Michael T Phan; Courtney Wong; Daniel M Tomaszewski; Zeev N Kain; Brooke Jenkins; Candice Donaldson; Michelle Fortier; Sun Yang Journal: J Contemp Pharm Prac Date: 2021-03-03